UNSPSC 51372325: Picenadol hydrochloride

This classification denotes an opioid receptor agonist C16H25NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29610N9WR1, chemically known as phenol, 3-(1,3-dimethyl-4-propyl-4-piperidinyl)-, hydrochloride, (+/-)-trans-, but more generally known as picenadol hydrochloride, which bears US NIH Compound Identifier 6917662. Most nations, for tariff and trade purposes, schedule picenadol hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PICENADOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Picenadol hydrochloride bears US NLM identifiers UMLS ID C2698802 and NCI Concept Code C76852. SMILES: CCC[C@]1(CCN(C[C@H]1C)C)C2CCCC(C2)O.CL.

UNSPSC 51372325 Picenadol hydrochloride is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The three recent opportunities tagged to this code—Seminole County's Naloxone and Drug Deactivation Systems procurement, Texas HHS Commission's Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions RFI, and Minnesota MMCAP's Generic Multi Source Pharmaceuticals and OTC Products RFP—represent pharmaceutical supply and pharmacy benefit management programs rather than purchases of picenadol hydrochloride specifically. State and local governments procuring under this code appear to be seeking pharmaceutical products and pharmacy services through competitive bidding, RFI market intelligence, and cooperative purchasing frameworks, with issuing bodies spanning county health departments, state health and human services agencies, and multistate cooperative alliances that serve state and local facilities.

Geographic activity centers on Florida, Texas, and Minnesota based on recent postings. The Seminole County IFB (due July 26, 2023) sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries; the Texas HHS Commission RFI (response deadline April 3, 2026) explored vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota MMCAP RFP (due March 26, 2026) solicited generic pharmaceuticals and OTC products for distribution across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026. The code shows no concentrated activity pattern and limited evidence of sustained procurement demand specifically for picenadol hydrochloride as a standalone product line.